{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:59:11Z","timestamp":1773838751824,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Although an increase in hepatitis C virus (HCV) prevalence from Northern to Southern Italy has been reported, the burden of asymptomatic individuals in different Italian regions is currently unknown.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A probabilistic approach, including a Markov chain for liver disease progression, was applied to estimate current HCV viraemic burden. The model defined prevalence by geographic area using an estimated annual historical HCV incidence by age, treatment rate, and migration rate from the Italian National database. Viraemic infection by age group was estimated for each region by main HCV transmission routes of individuals for stage F0\u2013F3 (i.e. patients without liver cirrhosis and thus potentially asymptomatic) and F4 (patients with liver cirrhosis, thus potentially symptomatic).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>By January 2020, it was estimated that there were 409,184 Italian individuals with HCV (prevalence of 0.68%; 95% CI: 0.54\u20130.82%), of which 300,171 (0.50%; 95% CI: 0.4\u20130.6%) were stage F0\u2013F3. Considering all individuals with HCV in stage F0\u2013F3, the geographical distributions (expressed as the proportion of HCV infected individuals by macroarea within the overall estimated number of F0\u2013F3 individuals and prevalence values, expressed as the percentage of individuals with HCV versus the overall number of individuals for each macroarea) were as follows: North 42.1% (0.45%; 95% CI: 0.36\u20130.55%), Central 24.1% (0.61%; 95% CI: 0.48\u20130.74%), South 23.2% (0.50%; 95% CI: 0.4\u20130.61%), and the Isles 10.6% (0.49%; 95% CI: 0.39\u20130.59%). The population of people who inject drugs accounted for 50.4% of all individuals infected (F0\u2013F3). Undiagnosed individuals (F0\u2013F3) were ~ 15\u00a0years younger (\u2053\u00a050\u00a0years) compared with patients with stage F4 (\u2053\u00a065\u00a0years), with similar age distributions across macroareas. In contrast to what has been reported on HCV epidemiology in Italy, an increasing trend in the proportion of potentially undiagnosed individuals with HCV (absolute number within the F0\u2013F3) from South (23.2%) to North (42.1%) emerged, independent of similar regional prevalence values.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This targeted approach, which addresses the specific profile of undiagnosed individuals, is helpful in planning effective elimination strategies by region in Italy and could be a useful methodology for other countries in implementing their elimination plans.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07042-w","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T08:24:24Z","timestamp":1642407864000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A mathematical model by route of transmission and fibrosis progression to estimate undiagnosed individuals with HCV in different Italian regions"],"prefix":"10.1186","volume":"22","author":[{"given":"Loreta A.","family":"Kondili","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Andreoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Alberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Lobello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Babudieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"De Michina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocco","family":"Merolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Marrocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Crax\u00ec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,17]]},"reference":[{"key":"7042_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","volume":"2","author":"Polaris Observatory HCV Collaborators","year":"2017","unstructured":"Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161\u201376.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"7042_CR2","unstructured":"World Health Organization. World Health Organization, Global Hepatitis Programme. Global hepatitis report, 2017. 2017. http:\/\/apps.who.int\/iris\/bitstream\/10665\/255016\/1\/9789241565455-eng.pdf?ua=1. Accessed 29 May 2019."},{"key":"7042_CR3","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nrgastro.2013.107","volume":"10","author":"B Hajarizadeh","year":"2013","unstructured":"Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10:553\u201362.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"7042_CR4","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jclinepi.2005.06.008","volume":"59","author":"MJ Sweeting","year":"2006","unstructured":"Sweeting MJ, De Angelis D, Neal KR, Ramsay ME, Irving WL, Wright M, et al. Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment. J Clin Epidemiol. 2006;59:144\u201352.","journal-title":"J Clin Epidemiol"},{"key":"7042_CR5","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889\u201398.","journal-title":"N Engl J Med"},{"key":"7042_CR6","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1306218","volume":"370","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211\u201321.","journal-title":"N Engl J Med"},{"key":"7042_CR7","unstructured":"WHO|Global health sector strategy on viral hepatitis 2016\u20132021. WHO. http:\/\/www.who.int\/hepatitis\/strategy2016-2021\/ghss-hep\/en\/. Accessed 29 May 2019."},{"key":"7042_CR8","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/hep.510260431","volume":"26","author":"V Guadagnino","year":"1997","unstructured":"Guadagnino V, Stroffolini T, Rapicetta M, Costantino A, Kondili LA, Menniti-Ippolito F, et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology. 1997;26:1006\u201311.","journal-title":"Hepatology"},{"key":"7042_CR9","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/gut.44.6.874","volume":"44","author":"S Bellentani","year":"1999","unstructured":"Bellentani S, Pozzato G, Saccoccio G, Crovatto M, Croc\u00e8 LS, Mazzoran L, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut. 1999;44:874\u201380.","journal-title":"Gut"},{"key":"7042_CR10","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/S0168-8278(00)80167-1","volume":"33","author":"G Maio","year":"2000","unstructured":"Maio G, d\u2019Argenio P, Stroffolini T, Bozza A, Sacco L, Tosti ME, et al. Hepatitis C virus infection and alanine transaminase levels in the general population: a survey in a southern Italian town. J Hepatol. 2000;33:116\u201320.","journal-title":"J Hepatol"},{"key":"7042_CR11","doi-asserted-by":"publisher","first-page":"100442","DOI":"10.1016\/j.epidem.2021.100442","volume":"34","author":"LA Kondili","year":"2021","unstructured":"Kondili LA, Andreoni M, Alberti A, Lobello S, Babudieri S, Roscini AS, et al. Estimated prevalence of undiagnosed HCV infected individuals in Italy: a mathematical model by route of transmission and fibrosis progression. Epidemics. 2021;34:100442.","journal-title":"Epidemics"},{"key":"7042_CR12","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1111\/liv.13901","volume":"38","author":"LA Kondili","year":"2018","unstructured":"Kondili LA, Robbins S, Blach S, Gamkrelidze I, Zignego AL, Brunetto MR, et al. Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? Liver Int. 2018;38:2190\u20138.","journal-title":"Liver Int"},{"key":"7042_CR13","unstructured":"National Hepatitis Plan. Piano nazionale per la prevenzione delle epatiti virali da virus B e C (PNEV). http:\/\/www.salute.gov.it\/ imgs\/C_17_pubblicazioni_2437_allegato.pdf. Accessed 11 Aug 2020."},{"key":"7042_CR14","unstructured":"Statistiche Istat. http:\/\/dati.istat.it\/Index.aspx. Accessed 31 May 2019."},{"key":"7042_CR15","unstructured":"SEIVA: Sistema Epidemiologico Integrato dell\u2019Epatite Virale Acuta. http:\/\/old.iss.it\/seieva\/."},{"key":"7042_CR16","unstructured":"Aggiornamento dati Registri AIFA DAAs-Epatite C cronica. :4."},{"issue":"6 Spec No.","key":"7042_CR17","first-page":"SP227","volume":"22","author":"MT Linthicum","year":"2016","unstructured":"Linthicum MT, Gonzalez YS, Mulligan K, Moreno GA, Dreyfus D, Juday T, et al. Value of expanding HCV screening and treatment policies in the United States. Am J Manag Care. 2016;22(6 Spec No.):SP227\u201335.","journal-title":"Am J Manag Care"},{"key":"7042_CR18","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1002\/hep.29399","volume":"66","author":"LA Kondili","year":"2017","unstructured":"Kondili LA, Romano F, Rolli FR, Ruggeri M, Rosato S, Brunetto MR, et al. Modeling cost-effectiveness and health gains of a \u201cuniversal\u201d versus \u201cprioritized\u201d hepatitis C virus treatment policy in a real-life cohort. Hepatology. 2017;66:1814\u201325.","journal-title":"Hepatology"},{"key":"7042_CR19","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/hep.24370","volume":"54","author":"JL Dienstag","year":"2011","unstructured":"Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim H-Y, et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011;54:396\u2013405.","journal-title":"Hepatology"},{"key":"7042_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta10210","volume":"10","author":"M Wright","year":"2006","unstructured":"Wright M, Grieve R, Roberts J, Main J, Thomas HC, UK Mild Hepatitis C Trial Investigators. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess. 2006;10:1-113 iii.","journal-title":"Health Technol Assess"},{"key":"7042_CR21","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.jval.2011.06.006","volume":"14","author":"R Townsend","year":"2011","unstructured":"Townsend R, McEwan P, Kim R, Yuan Y. Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. Value Health. 2011;14:1068\u201377.","journal-title":"Value Health"},{"key":"7042_CR22","unstructured":"Relazione Annuale Al Parlamento Sullo Stato Delle Tossicodipendenze in Italia 2002. 2002. http:\/\/www.edscuola.it\/archivio\/handicap\/tossicodipendenze02.pdf."},{"key":"7042_CR23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ejim.2018.02.015","volume":"53","author":"A Andriulli","year":"2018","unstructured":"Andriulli A, Stroffolini T, Mariano A, Valvano MR, Grattagliano I, Ippolito AM, et al. Declining prevalence and increasing awareness of HCV infection in Italy: a population-based survey in five metropolitan areas. Eur J Intern Med. 2018;53:79\u201384.","journal-title":"Eur J Intern Med"},{"key":"7042_CR24","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1017\/S0950268817001947","volume":"145","author":"SHI Hofstraat","year":"2017","unstructured":"Hofstraat SHI, Falla AM, Duffell EF, Hahn\u00e9 SJM, Amato-Gauci AJ, Veldhuijzen IK, et al. Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU\/EEA: a systematic review. Epidemiol Infect. 2017;145:2873\u201385.","journal-title":"Epidemiol Infect"},{"key":"7042_CR25","unstructured":"The Italian Liver Patients\u2019 Association (EpaC). https:\/\/www.epac.it\/. Accessed 20 Jul 2019."},{"key":"7042_CR26","unstructured":"Li Bassi L. Le nuove modalit\u00e0 di approccio alla patologia e misure in itinere. 2019. https:\/\/www.epac.it\/cm-files\/2019\/10\/22\/programma-preliminare-convegno-hcv-5-novembre.pdf."},{"key":"7042_CR27","unstructured":"A.I.S.F, Associazione Italiana per lo studio del Fegato. Epidemiologia delle Epatopatie Acute e Croniche in Italia. https:\/\/www.webaisf.org\/wp-content\/uploads\/2019\/01\/epidemiologia_.pdf."},{"key":"7042_CR28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/liv.13647","volume":"38","author":"ML Shiffman","year":"2018","unstructured":"Shiffman ML. The next wave of hepatitis C virus: the epidemic of intravenous drug use. Liver Int. 2018;38:34\u20139.","journal-title":"Liver Int"},{"key":"7042_CR29","unstructured":"Hickman M, Martin NK, European Monitoring Centre for Drugs and Drug Addiction. Hepatitis C among drug users in Europe: epidemiology, treatment and prevention. Luxembourg: Publications Office; 2016. http:\/\/bookshop.europa.eu\/uri?target=EUB:NOTICE:TDXD16002:EN:HTML. Accessed 20 Aug 2020."},{"key":"7042_CR30","unstructured":"Italy In Figures: 2015. https:\/\/www.istat.it\/en\/files\/2015\/09\/ItalyinFigures2015.pdf."},{"key":"7042_CR31","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1111\/liv.14408","volume":"40","author":"LA Kondili","year":"2020","unstructured":"Kondili LA, Gamkrelidze I, Blach S, Marcellusi A, Galli M, Petta S, et al. Optimization of hepatitis C virus screening strategies by birth cohort in Italy. Liver Int. 2020;40:1545\u201355.","journal-title":"Liver Int"},{"key":"7042_CR32","unstructured":"Galli M. Epatite C: 71 milioni di euro stanziati in Italia per screening gratuiti. Osservatorio Malattie Rare. https:\/\/www.osservatoriomalattierare.it\/epatite-c\/15694-epatite-c-71-milioni-di-euro-stanziati-in-italia-per-screening-gratuiti. Accessed 23 Sep 2020."},{"key":"7042_CR33","unstructured":"Monitoraggio settimanale Covid-19, report dal 13 al 19 luglio. http:\/\/www.salute.gov.it\/portale\/news\/documenti\/Epi_aggiornamenti\/allegati\/Punti_chiave_e_tabella_incidenza_13_19_luglio_2020.pdf."},{"key":"7042_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2020.05.040","author":"LA Kondili","year":"2020","unstructured":"Kondili LA, Marcellusi A, Ryder S, Crax\u00ec A. Will the COVID-19 pandemic affect HCV disease burden? Dig Liver Dis. 2020. https:\/\/doi.org\/10.1016\/j.dld.2020.05.040.","journal-title":"Dig Liver Dis"},{"key":"7042_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.07.042","author":"S Blach","year":"2020","unstructured":"Blach S, Kondili LA, Aghemo A, Cai Z, Dugan E, Estes C, et al. Impact of COVID-19 on global hepatitis C elimination efforts. J Hepatol. 2020. https:\/\/doi.org\/10.1016\/j.jhep.2020.07.042.","journal-title":"J Hepatol"},{"key":"7042_CR36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/ijlh.13207","volume":"42","author":"S Buoro","year":"2020","unstructured":"Buoro S, Di Marco F, Rizzi M, Fabretti F, Lorini FL, Cesa S, et al. Papa Giovanni XXIII Bergamo Hospital at the time of the COVID-19 outbreak: letter from the warfront\u2026. Int J Lab Hematol. 2020;42:8\u201310.","journal-title":"Int J Lab Hematol"},{"key":"7042_CR37","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.3748\/wjg.v24.i41.4617","volume":"24","author":"LE Adinolfi","year":"2018","unstructured":"Adinolfi LE, Rinaldi L, Nevola R. Chronic hepatitis C, atherosclerosis and cardiovascular disease: what impact of direct-acting antiviral treatments? World J Gastroenterol. 2018;24:4617\u201321.","journal-title":"World J Gastroenterol"},{"issue":"Suppl 10","key":"7042_CR38","first-page":"19","volume":"89","author":"G Massimo","year":"2018","unstructured":"Massimo G, Annalisa R, van den Bogaart L, Cristina N, Andrea G. HCV and immigration in Italy. Acta Biomed. 2018;89(Suppl 10):19\u201332.","journal-title":"Acta Biomed"},{"key":"7042_CR39","doi-asserted-by":"publisher","unstructured":"Coppola N, Alessio L, Onorato L, Sagnelli C, Macera M, Sagnelli E, et al. Epidemiology and management of hepatitis C virus infections in immigrant populations. Infect Dis Poverty. 2019;8.https:\/\/doi.org\/10.1186\/s40249-019-0528-6.","DOI":"10.1186\/s40249-019-0528-6"},{"key":"7042_CR40","doi-asserted-by":"publisher","first-page":"e02114","DOI":"10.1016\/j.heliyon.2019.e02114","volume":"5","author":"U Fedeli","year":"2019","unstructured":"Fedeli U, Avossa F, Ferroni E, De Paoli A, Donato F, Corti MC. Prevalence of chronic liver disease among young\/middle-aged adults in Northern Italy: role of hepatitis B and hepatitis C virus infection by age, sex, ethnicity. Heliyon. 2019;5:e02114. https:\/\/doi.org\/10.1016\/j.heliyon.2019.e02114.","journal-title":"Heliyon."},{"key":"7042_CR41","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12879-017-2908-5","volume":"18","author":"AM Falla","year":"2018","unstructured":"Falla AM, Ahmad AA, Duffell E, Noori T, Veldhuijzen IK. Estimating the scale of chronic hepatitis C virus infection in the EU\/EEA: a focus on migrants from anti-HCV endemic countries. BMC Infect Dis. 2018;18:42.","journal-title":"BMC Infect Dis"},{"key":"7042_CR42","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1136\/jech.2006.051599","volume":"62","author":"MF Vescio","year":"2008","unstructured":"Vescio MF, Longo B, Babudieri S, Starnini G, Carbonara S, Rezza G, et al. Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis. J Epidemiol Community Health. 2008;62:305\u201313.","journal-title":"J Epidemiol Community Health"},{"key":"7042_CR43","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.4254\/wjh.v7.i21.2323","volume":"7","author":"R Zampino","year":"2015","unstructured":"Zampino R, Coppola N, Sagnelli C, Di Caprio G, Sagnelli E. Hepatitis C virus infection and prisoners: Epidemiology, outcome and treatment. World J Hepatol. 2015;7:2323\u201330.","journal-title":"World J Hepatol"},{"key":"7042_CR44","doi-asserted-by":"publisher","first-page":"103055","DOI":"10.1016\/j.drugpo.2020.103055","volume":"90","author":"V Fiore","year":"2021","unstructured":"Fiore V, De Matteis G, Ranieri R, Saderi L, Pontali E, Muredda A, et al. HCV testing and treatment initiation in an Italian prison setting: a step-by-step model to micro-eliminate hepatitis C. Int J Drug Policy. 2021;90:103055.","journal-title":"Int J Drug Policy"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07042-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07042-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07042-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T08:25:19Z","timestamp":1642407919000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07042-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,17]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7042"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07042-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,17]]},"assertion":[{"value":"7 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LAK received teaching grants from AbbVie and Gilead. MA received advisor\/speaker\/research Grant from AbbVie, Gilead, MSD, ViiV, Janssen-Cilag, and BMS. AA received advisor\/research Grants from AbbVie, Gilead, and MSD. SB received advisor\/research Grants from AbbVie, Gilead, and Otsuka. AC, SL, and WM have nothing to disclose. RM and ADM are AbbVie employees and may own AbbVie stocks and options.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}